SINGAPORE, Sept. 14 (Xinhua) — Singapore’s Health Sciences Authority (HSA) has granted provisional approval for the use of a bivalent COVID-19 booster vaccine in Singapore, the first of its kind approved in the country.
The Spikevax Bivalent Original/Omicron COVID-19 vaccine produced through Moderna includes two parts that target the original SARS-CoV-2 strain and the Omicron BA. 1 variant, respectively, the HSA said in an announcement published Wednesday.
It is legal to use it as a booster vaccine in other people over the age of 18, who have won the number one vaccination with COVID-19 vaccines, the HSA said.
The HSA said it thoroughly reviewed knowledge from preclinical studies, clinical trials in human volunteers, production and quality controls from Moderna, and assessed that the benefits outweigh the dangers of the bivalent vaccine as a booster to protect against COVID-19 as the virus continues. evolve.
The HSA will continue to actively monitor vaccine protection and take action if significant protection issues are identified, he noted.
According to information from Singapore’s Ministry of Health, at noon on Wednesday, the country recorded a total of 1. 87 million cases of COVID-19, with a death toll of 1604.